Search results for "Enzyme Inhibitor"

showing 10 items of 627 documents

Hypoxia-induced dysfunction of rat diaphragm

2004

Contains fulltext : 47331.pdf (Publisher’s version ) (Closed access) Oxidants may play a role in hypoxia-induced respiratory muscle dysfunction. In the present study we hypothesized that hypoxia-induced impairment in diaphragm contractility is associated with elevated peroxynitrite generation. In addition, we hypothesized that strenuous contractility of the diaphragm increases peroxynitrite formation. In vitro force-frequency relationship, isotonic fatigability, and nitrotyrosine levels were assessed under hypoxic (Po(2) approximately 6.5 kPa) and hyperoxic (Po(2) approximately 88.2 kPa) control conditions and also in the presence of authentic peroxynitrite (60 min), ebselen (60 min), and t…

Pulmonary and Respiratory MedicineAzolesMalemedicine.medical_specialtyPhysiologyDiaphragmAetiology screening and detection [ONCOL 5]In Vitro TechniquesIsoindolesNitric oxideContractilitychemistry.chemical_compoundTranslational research [ONCOL 3]Physiology (medical)Internal medicineOrganoselenium CompoundsPeroxynitrous AcidmedicineRespiratory muscleAnimalsRespiratory systemEnzyme InhibitorsRats WistarHypoxiaHeart lung and circulation [UMCN 2.1]Renal disorder [IGMD 9]omega-N-MethylarginineNitrotyrosineCell BiologyHypoxia (medical)Tissue engineering and pathology [NCMLS 3]musculoskeletal systemRatsPathogenesis and modulation of inflammation [N4i 1]EndocrinologychemistryBiochemistryMuscle FatigueTyrosineRat DiaphragmLipid Peroxidationmedicine.symptomPeroxynitriteMuscle ContractionAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
researchProduct

Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reperfusion on the beating heart.

2002

AbstractObjective: Early coronary reperfusion of the ischemic myocardium is a desired therapeutic goal to preserve myocardium. However, reperfusion itself contributes to an additional myocardial injury (ie, reperfusion injury), which has been attributed to neutrophil infiltration with subsequent release of proteases and oxygen-derived radicals. We studied the effects of the serine protease inhibitor aprotinin (Trasylol) on myocardial ischemia and reperfusion in a rat model. Methods: The effects of aprotinin (5000 and 20,000 U/kg) were examined in vivo in a rat model of regional myocardial ischemia (20 minutes) and long-term reperfusion (24 hours). Cardioprotecive effects were determined by …

Pulmonary and Respiratory MedicineMaleProteasesCardiotonic AgentsSerine Proteinase InhibitorsNeutrophilsHeart VentriclesIschemiaMyocardial IschemiaApoptosisMyocardial ReperfusionMyocardial Reperfusion InjuryPharmacologyRats Sprague-DawleyLeukocyte CountAprotininIn vivoMedicineAnimalsAprotininCreatine KinasePeroxidaseCardioprotectionbiologyDose-Response Relationship Drugbusiness.industryMyocardiumModels Cardiovascularmedicine.diseaseCombined Modality TherapyRatsDisease Models AnimalTreatment OutcomeEnzyme inhibitorAnesthesiabiology.proteinSurgeryCreatine kinaseCardiology and Cardiovascular MedicinebusinessReperfusion injuryBiomarkersmedicine.drugThe Journal of thoracic and cardiovascular surgery
researchProduct

Cercospora beticola toxins. Part XVII. The role of the beticolin/Mg2+ complexes in their biological activity Study of plasma membrane H+-ATPase, vacu…

1996

Beticolin-1 and beticolin-2, yellow toxins produced by the phytopathogenic fungus Cercospora beticola, inhibit the plasma membrane H(+)-ATPase. Firstly, since beticolins are able to form complexes with Mg2+, the role of the beticolin/Mg2+ complexes in the inhibition of the plasma membrane proton pump has been investigated. Calculations indicate that beticolins could exist under several forms, in the H(+)-ATPase assay mixture, both free or complexed with Mg2+. However, the percentage inhibition of the H(+)-ATPase activity is correlated to the concentration of one single form of beticolin, the dimeric neutral complex Mg2H2B2, which appears to be the active form involved in the H(+)-ATPase inh…

Pyrophosphatase H+-StereochemistryATPaseAcid PhosphatasePhosphataseBiophysicsBiological Transport ActiveHeterocyclic Compounds 4 or More RingsZea maysBiochemistryMagnesium ion complexH+- PyrophosphataseMagnesiumEnzyme InhibitorsPyrophosphatasesInhibitionchemistry.chemical_classificationATPase H+-biologyChemistryVacuolar hCell MembraneSubstrate (chemistry)Biological activityCell BiologyMycotoxinsAlkaline PhosphataseCercospora beticolabiology.organism_classificationInorganic PyrophosphataseProton-Translocating ATPasesBeticolinMembraneEnzymeBiochemistryVacuolesbiology.proteinH+- ATPaseBiochimica et Biophysica Acta (BBA) - Biomembranes
researchProduct

Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 …

2021

Background The use of Renin-Angiotensin system inhibitors (RASi) in patients with coronavirus disease 2019 (COVID-19) has been questioned because both share a target receptor site. Methods HOPE-COVID-19 (NCT04334291) is an international investigator-initiated registry. Patients are eligible when discharged after an in-hospital stay with COVID-19, dead or alive. Here, we analyze the impact of previous and continued in-hospital treatment with RASi in all-cause mortality and the development of in-stay complications. Results We included 6503 patients, over 18 years, from Spain and Italy with data on their RASi status. Of those, 36.8% were receiving any RASi before admission. RASi patients were …

QA75Malemedicine.medical_specialtyHeart diseaseInfecciones por coronavirusmedicine.medical_treatmentInhibidores enzimáticosPopulationClinical InvestigationsEnfermedad transmisibleAngiotensin-Converting Enzyme InhibitorsSistema renina-angiotensinaComorbidity030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineRisk FactorsOutcome Assessment Health CareSeverity of illnessmedicineHumansRegistries030212 general & internal medicineMedical prescriptioneducationHeart FailureMechanical ventilationeducation.field_of_studySARS-CoV-2business.industryCOVID-19Middle AgedPrognosismedicine.diseaseR1Respiration ArtificialComorbidityHospitalizationItalySpainHeart failureEmergency medicineFemaleObservational studyCardiology and Cardiovascular MedicinebusinessAmerican Heart Journal
researchProduct

Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays

2006

QSAR (quantitative structure-activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model Class=-96.067+1.988 x 10(2)X0Av +9 1.907 BIC3 + 6.853 CIC1 in the training set. External validation processes to assess the robustness and predictive pow…

Quantitative structure–activity relationshipDatabases FactualStereochemistryTyrosinaseQuantitative Structure-Activity RelationshipComputational biologyLigandsChemometricschemistry.chemical_compoundPiperidinesDrug DiscoveryComputer SimulationPharmacologyVirtual screeningbiologyChemistryOrganic ChemistryIn vitro toxicologyComputational BiologyDiscriminant AnalysisReproducibility of ResultsGeneral MedicineLinear discriminant analysisEnzyme inhibitorDrug Designbiology.proteinPeptidesKojic acidSoftwareEuropean Journal of Medicinal Chemistry
researchProduct

New tyrosinase inhibitors selected by atomic linear indices-based classification models.

2005

In the present report, the use of the atom-based linear indices for finding functions that discriminate between the tyrosinase inhibitor compounds and inactive ones is presented. In this sense, discriminant models were applied and globally good classifications of 93.51% and 92.46% were observed for non-stochastic and stochastic linear indices best models, respectively, in the training set. The external prediction sets had accuracies of 91.67% and 89.44%. In addition, these fitted models were used in the screening of new cycloartane compounds isolated from herbal plants. A good behavior is shown between the theoretical and experimental results. These results provide a tool that can be used i…

Quantitative structure–activity relationshipMolecular modelStereochemistryTyrosinaseClinical BiochemistryMolecular ConformationPharmaceutical ScienceQuantitative Structure-Activity RelationshipBiochemistrySensitivity and SpecificityChemometricsDrug DiscoveryComputer SimulationEnzyme InhibitorsMolecular BiologyTraining setChemistryMonophenol MonooxygenaseOrganic ChemistryLinear discriminant analysisTriterpenesDiscriminantModels ChemicalTopological indexMolecular MedicineBiological systemBioorganicmedicinal chemistry letters
researchProduct

Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors

2019

[EN] The development and advancement of prostate cancer (PCa) into stage 4, where it metastasize, is a major problem mostly in elder males. The growth of PCa cells is stirred up by androgens and androgen receptor (AR). Therefore, therapeutic strategies such as blocking androgens synthesis and inhibiting AR binding have been explored in recent years. However, recently approved drugs (or in clinical phase) failed in improving the expected survival rates for this metastatic-castration resistant prostate cancer (mCRPC) patients. The selective CYP17A1 inhibition of 17,20-lyase route has emerged as a novel strategy. Such inhibition blocks the production of androgens everywhere they are found in t…

Quantitative structure–activity relationshipStereochemistry01 natural sciencesBiochemistryStructure-Activity Relationship3D-QSAR pharmacophore modelDrug DiscoveryCytochrome P-450 Enzyme InhibitorsHumansStructure–activity relationshipCYP17A1 InhibitorMolecular BiologyDensity Functional TheoryVirtual screeningDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryOrganic ChemistryProspective computational designSteroid 17-alpha-Hydroxylasecomputer.file_format1720-lyase selective inhibitionProtein Data BankLyase0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)CYP17A1 inhibitorsMetastatic-castration resistant prostate cancerPharmacophorecomputer
researchProduct

Vanilloid Derivatives as Tyrosinase Inhibitors Driven by Virtual Screening-Based QSAR Models

2010

A number of vanilloids have been tested as tyrosinase inhibitors using Ligand-Based Virtual Screening (LBVS) driven by QSAR (Quantitative Structure-Activity Relationship) models as the multi-agent classification system. A total of 81 models were used to screen this family. Then, a preliminary cluster analysis of the selected chemicals was carried out based on their bioactivity to detect possible similar substructural features among these compounds and the active database used in the QSAR model construction. The compounds identified were tested in vitro to corroborate the results obtained in silico. Among them, two chemicals, isovanillin (K(M) (app) = 1.08 mM) near to kojic acid (reference d…

Quantitative structure–activity relationshipStereochemistryTyrosinaseIn silicoQuantitative Structure-Activity RelationshipPharmaceutical ScienceIsovanillinModels BiologicalSkin DiseasesVanilloidsAnalytical Chemistrychemistry.chemical_compoundCluster AnalysisHumansEnvironmental ChemistryComputer SimulationEnzyme InhibitorsSpectroscopyVirtual screeningMonophenol MonooxygenaseReference drugCombinatorial chemistrychemistryBenzaldehydesDrug DesignKojic acidAlgorithmsDrug Testing and Analysis
researchProduct

Strict blood-pressure control and progression of renal failure in children

2009

PubMedID: 19846849 BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting- enzyme (ACE) inhibitor. METHODS: After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m2 of body-surface area) received ramipril at a dose of 6 mg per square meter of bodysurface area per day…

RamiprilMaleMean arterial pressuremedicine.medical_specialtyAdolescentUrologyRenal functionAngiotensin-Converting Enzyme InhibitorsBlood PressureKaplan-Meier EstimateRamiprilmedicineClinical endpointHumansRenal Insufficiency ChronicChildDEPARTMENTSAntihypertensive AgentsProteinuriabusiness.industryHazard ratioGeneral MedicineBlood Pressure Monitoring Ambulatorymedicine.diseaseSurgeryProteinuriaBlood pressureChild PreschoolCreatinineHypertensionDisease ProgressionKidney Failure ChronicDrug Therapy CombinationFemalemedicine.symptombusinessKidney diseasemedicine.drugGlomerular Filtration Rate
researchProduct

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

2012

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups.…

RamiprilMalemedicine.medical_specialtyAmbulatory blood pressureDiastoleAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialRamiprillawInternal medicineInternal MedicinemedicineHumansLongitudinal StudiesTelmisartanAntihypertensive AgentsAgedbusiness.industryambulatory blood pressure antihypertensive treatment high cardiovascular risk angiotensin-converting enzyme inhibitors angiotensin receptor blockersMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedEndocrinologyBlood pressureTreatment OutcomeTarget drugAmbulatoryHypertensionCardiologyBenzimidazolesDrug Therapy CombinationFemaleTelmisartanbusinessmedicine.drug
researchProduct